Monday, 19 October 2026European Markets

PORCELEYNE FLES Stock 16.67% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with PORCELEYNE FLES (PORF.AS) rising 16.67% to €13.30 on Thursday while AEX-Index jumped 0.08% to €908.36.

PORCELEYNE FLES's last close was €11.40, 28.75% below its 52-week high of €16.00.

About PORCELEYNE FLES

B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" produces and sells Delft Blue decorative pottery and modern pottery products in the Netherlands. It is involved in the purchasing, operation, management, and leasing of real estate properties. The company was founded in 1653 and is based in Delft, the Netherlands.

Earnings Per Share

As for profitability, PORCELEYNE FLES has a trailing twelve months EPS of €0.15.

PE Ratio

PORCELEYNE FLES has a trailing twelve months price to earnings ratio of 88.67. Meaning, the purchaser of the share is investing €88.67 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.02%.

More news about PORCELEYNE FLES (PORF.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com